Cost effectiveness of treatment strategies for high risk prostate cancer.
Roman O KowalchukHayeon KimWilliam S HarmsenElizabeth B JeansLindsay K MorrisTrey C MullikinRobert C MillerWilliam W WongCarlos E VargasDaniel M TrifilettiRyan M PhillipsC R ChooBrian J DavisSushil BeriwalRahul D TendulkarBradley J StishWilliam G BreenMark R WaddlePublished in: Cancer (2022)
EBRT with LDR brachytherapy boost may be a cost-effective treatment strategy compared with EBRT alone and radical prostatectomy for HRPC, demonstrating high-value care. The current analysis suggests that a reduction in biochemical failure alone can result in cost-effective care, despite no change in overall survival.